Plasmacure
Plasmacure is in the business of healing chronic wounds. In fact, it leads the transition from traditional standards of wound care to effective, technology-based solutions. Wound care is a € >70B global industry. Aging populations and the onset of conditions underlying chronic wounds, such as diabetes, will only increase pressure on healthcare cost. Current care protocols for treatment of complex wounds have limited proven effectiveness, are expensive and/or are cumbersome to patients. Treatment with Plasmacure’s patented PLASOMA cold plasma system (CE-marked, medical device class IIb), was demonstrated to be 2.5x more effective at closing complex wounds than these traditional methods (in a randomized controlled trial, RCT). The IP-protected (US, EU, UK and CN) solution consists of a ‘pulser unit’ and ‘cold plasma pads’. The pulser unit generates a high voltage that creates a plasma (ionized air). The technical design ensures a safe return path for the current. The (disposable) cold plasma pad delivers the plasma directly to the wound.
Learn more- Homebase High Tech Campus 11
Treating patients with PLASOMA can save >40% in healthcare cost and >50% in staff workload. PLASOMA is the only cold plasma treatment solution for wound care indicated safe and effective for both in-clinic and home use through a peer-reviewed RCT. Whether for diabetic foot ulcers, leg ulcers, pressure ulcers, burn wounds, etc, PLASOMA treatments last only 2 minutes per session and can easily be fitted into existing care routines.
Team Plasmacure has been successfully scaling the business in The Netherlands and in selected other markets.
It is privileged to work with esteemed healthcare industry partners and investors that include NextGen Ventures, OostNL and The European Economic Council.